European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
EANM Springer Prizes 2020 awarded at EANM 2021	210
Towards molecular imaging-guided intervention theatres in oncology	165
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	154
New technologies—the best is yet to come	146
Nuclear imaging and therapy in oncology in Poland in 2021–2022	137
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”	133
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	122
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	122
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	117
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	117
Cinematic rendering of [18F]FDG-PET/MR	109
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	104
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study	100
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	89
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	87
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	86
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	85
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	83
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	83
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?	81
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	80
Cadherin-17 as a target for the immunoPET of adenocarcinoma	80
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	79
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer	77
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	77

[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	73
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	72
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	71
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer	71
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	68
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	66
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	65
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	65
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	64
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	63
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	62
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	62
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	62
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	61
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI	60
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	59
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	59
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	57
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	57
Seasonal variation in D2/3 dopamine receptor availability in the human brain	57
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	56
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	56
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	55
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	55
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results	55
Andrea Varrone, Silvia Morbelli, Valentina Garibotto (Editors). Clinical nuclear medicine in neurology. An Atlas of challenging cases.	54
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	54
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	54
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	54
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	53
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	53
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	51
Positive [18F]fluoroethyltyrosine PET/MRI in suspected recurrence of growth hormone–producing pituitary adenoma in a paediatric patient	51
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	51
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	50
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	49
Development of STING probes and visualization of STING in multiple tumor types	49
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	49
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	48
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	47
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	46
DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with 131I	45
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	45
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	45
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	45
Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	45
Intra-vagal parathyroid adenoma on digital PET/CT with 18F-fluorocholine	45
Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	45
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	43
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	43

Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	42
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	41
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	41
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	41
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	41
68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination	41
A cutting-edge technology for the future of nuclear medicine	41
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	40
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	40
From radiotracer to radiopharmaceutical: a philosophical approach	40
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	40
Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis	40
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	40
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	40
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	40
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	39
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	39
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	39
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	38
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	38
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	38
Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement	38
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	37
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	36
[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer	36
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients	36
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	36
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	36
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	36
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	36
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	36
About ESTMABLE2: non-inferiority doesn’t equal better	35
Guiding principles on the education and practice of theranostics	35
Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer	35
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	35
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	35
Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	35
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	34
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	34
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	34
Can Q.Clear reconstruction be used to improve [68 Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?	34
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	34
Diagnostic performance of deep learning models for detecting bone metastasis on whole-body bone scan in prostate cancer	34
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	34
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	33
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	33
PET imaging utilization and trends in Germany: a comprehensive survey	33
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	33
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	33
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	32
Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform	32
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	32
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	32
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	32
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	32
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	32
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	32
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	32
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	31
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	31
PET imaging of new target CDK19 in prostate cancer	31
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease	31
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	31
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	31
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	31
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	31
Molecular imaging: The bridge from human phenome to personalized precision medicine	31
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	31
Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients	30
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth	30
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	30
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	30
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	30
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	30
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	30
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	30
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	30
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	30
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	29
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	29

Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment del	29
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	29
Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study	29
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	29
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	28
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	28
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	28
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	28
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	28
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	28
Size-changeable nanoprobes for the combined radiotherapy and photodynamic therapy of tumor	28
Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	28
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	28
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	28
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	27
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	27
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer	27
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	27
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	27
Decoupling of regional neural activity and inter-regional functional connectivity in Alzheimer’s disease: a simultaneous PET/MR study	27
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	27
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	27
Collection on molecular imaging in cardiac amyloidosis	27
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	27
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	27
Both [68Ga]Ga-FAPI and [18F]FDG PET/CT missed bone metastasis in a patient with breast cancer	26
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	26
Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners	26
Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis	26
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	26
Expert consensus on workflow of PET/CT with long axial field-of-view	26
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	26
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	26
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	26
Myocardial perfusion SPECT findings in postCOVID period	26
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	26
Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients	26
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	25
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	25
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	25
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	25
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial	25
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	25
[68Ga]Ga-FAPI PET/CT imaging of brown tumors in a patient with primary hyperparathyroidism	25
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	25
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	24
A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition	24
Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives	24
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	24
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	24
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	24
Total-body pediatric PET is ready for prime time	24
The role of radiographers in nuclear medicine; the link between patient and technology	24
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	24
PET imaging of animal models with depressive-like phenotypes	24
Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics	24
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	24
SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective	24
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	24
In vivo methods for imaging blood–brain barrier function and dysfunction	24
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	24
High-resolution pediatric age–specific 18F-FDG PET template: a pilot study in epileptogenic focus localization	23
Utilizing artificial intelligence to detect cardiac amyloidosis in patients with severe aortic stenosis: A step forward to diagnose the underdiagnosed	23
Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis	23
Hybrid training in nuclear medicine: where are we going to?	23
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China	23
Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease	23
Pigmented villonodular synovitis detected by [68Ga]Ga-FAPI-04 PET/CT	23
Exploring coronary microvascular function by quantitative CZT-SPECT: a small step or giant leap for INOCA patients?	23
L.J. Koenig, D. Tamimi, S.E. Perschbacher, H. Demirturk. Diagnostic imaging: oral and maxillofacial. 3rd Edition	23
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	23
In memoriam: Marion Hendriks-de Jong	22
Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer’s disease: the RJNB-D study	22
Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study	22
Correction to: Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer	22
Correction To: Coronary artery calcium measurement on attenuation correction computed tomography using artificial intelligence: correlation with coronary flow capacity and prognosis	22
99mTc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel	22
Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models	22
Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study	22
An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes	22
Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience	22
Individual cerebellar metabolic connectome in patients with MTLE and NTLE associated with surgical prognosis	22
Decrease in the cortex/striatum metabolic ratio on [18F]-FDG PET: a biomarker of autoimmune encephalitis	22
Correction to: Hetero-bivalent agents targeting FAP and PSMA	22
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)	22
FAP inhibitors: are we really using the best method to evaluate the residence time?	22
Positive amyloid and tau PET in an early-onset Alzheimer’s disease with a rare PSEN1 (Arg278Gly) mutation	22
Dose–response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases	21
Dania Tamimi (Editor) Specialty imaging: Temporomandibular Joint and Sleep-Disordered Breathing, 2nd Edition	21
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer	21
[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT	21
The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients	21
Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy	21
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre	21
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition	21